ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Irisin Restrains Oligodendroglial Ferroptosis to Preserve White Matter After Traumatic Brain Injury via AMPK Activation.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Traumatic brain injury (TBI) results in diffuse white matter (WM) damage, which is a major determinant of death and long-term disability. Irisin, a myokine with promising neuroprotective effects, but whether irisin modulates WM injury after TBI remains unknown. Using a controlled cortical impact (CCI) mouse model, we evaluated post-TBI irisin expression and its protective effects on neurological function and WM integrity. Multiple experimental approaches, such as RT-qPCR, Liperfluo staining, Western blot, and transmission electron microscopy, were employed to assess oligodendrocyte precursor cell (OPC) ferroptosis and relevant signaling pathways. The xCT inhibitor IKE, AMPK inhibitor Compound C, and cFOS siRNAs were employed to explore the underlying mechanisms. TBI transiently suppressed peri-lesional irisin expression. Irisin treatment improved motor and cognitive performance, attenuated demyelination and the loss of OPCs in peri-lesional WM. Mechanistically, TBI triggered an xCT-dependent ferroptotic program, which was counteracted by irisin. Additionally, irisin activated AMPK, thereby suppressing the expression of cFOS, a transcriptional repressor of xCT. Compound C abrogated the protective effects of irisin and cFOS silencing, indicating an AMPK-dependent irisin-cFOS-xCT/GPX4 axis. TBI suppresses endogenous irisin. Restoration with exogenous irisin protects OPCs against ferroptosis, thereby preserving WM integrity and ultimately improving functional recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.